Dr. Hoffman-Censits on Biomarker Development in Urothelial Carcinoma

Jean Hoffman-Censits, MD
Published: Friday, Sep 29, 2017



Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

There are currently no biomarkers for determining which patients should receive immunotherapy, targeted therapy, or platinum chemotherapy, states Hoffman-Censits.

Biomarkers are being investigated in prospective trials, but all the data is limited to those patients in clinical trials, explains Hoffman-Censits.

SELECTED
LANGUAGE


Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

There are currently no biomarkers for determining which patients should receive immunotherapy, targeted therapy, or platinum chemotherapy, states Hoffman-Censits.

Biomarkers are being investigated in prospective trials, but all the data is limited to those patients in clinical trials, explains Hoffman-Censits.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Biomarkers: How Can I Utilize Tumor Mutational Burden in My Practice?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x